Prosthetic joint infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Prosthetic joint infections – Pipeline Review, H2 2016’, provides an overview of the Prosthetic joint infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prosthetic joint infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prosthetic joint infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Prosthetic joint infections

The report reviews pipeline therapeutics for Prosthetic joint infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Prosthetic joint infections therapeutics and enlists all their major and minor projects

The report assesses Prosthetic joint infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Prosthetic joint infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Prosthetic joint infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prosthetic joint infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cempra Inc

Motif Bio Plc

Nabriva Therapeutics AG

Telephus Medical LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Prosthetic joint infections Overview 6

Therapeutics Development 7

Pipeline Products for Prosthetic joint infections - Overview 7

Prosthetic joint infections - Therapeutics under Development by Companies 8

Prosthetic joint infections - Pipeline Products Glance 9

Late Stage Products 9

Early Stage Products 10

Unknown Stage Products 11

Prosthetic joint infections - Products under Development by Companies 12

Prosthetic joint infections - Companies Involved in Therapeutics Development 13

Cempra Inc 13

Motif Bio Plc 14

Nabriva Therapeutics AG 15

Telephus Medical LLC 16

Prosthetic joint infections - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

EPP-001 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

fusidic acid - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

lefamulin acetate - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

MTF-101 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

TNP-2092 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

TPH-101 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Prosthetic joint infections - Dormant Projects 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

List of Tables

Number of Products under Development for Prosthetic joint infections, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Comparative Analysis by Unknown Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Prosthetic joint infections – Pipeline by Cempra Inc, H2 2016 13

Prosthetic joint infections – Pipeline by Motif Bio Plc, H2 2016 14

Prosthetic joint infections – Pipeline by Nabriva Therapeutics AG, H2 2016 15

Prosthetic joint infections – Pipeline by Telephus Medical LLC, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Prosthetic joint infections – Dormant Projects, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for Prosthetic joint infections, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports